Aquestive Therapeutics (AQST) Projected to Post Quarterly Earnings on Wednesday

Aquestive Therapeutics (NASDAQ:AQST) is projected to announce its Q3 2025 results after the market closes on Wednesday, November 5th. Analysts expect the company to announce earnings of ($0.13) per share and revenue of $12.9440 million for the quarter. Aquestive Therapeutics has set its FY 2025 guidance at EPS.Investors can check the company’s upcoming Q3 2025 earningsummary page for the latest details on the call scheduled for Thursday, November 6, 2025 at 8:00 AM ET.

Aquestive Therapeutics (NASDAQ:AQST) last issued its quarterly earnings results on Monday, August 11th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.18) by $0.04. The business had revenue of $10.00 million during the quarter, compared to the consensus estimate of $11.32 million. On average, analysts expect Aquestive Therapeutics to post $0 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Aquestive Therapeutics Price Performance

Shares of Aquestive Therapeutics stock opened at $6.82 on Monday. The company has a 50-day moving average of $5.65 and a 200 day moving average of $4.17. The firm has a market cap of $680.09 million, a price-to-earnings ratio of -9.74 and a beta of 1.79. Aquestive Therapeutics has a 1 year low of $2.12 and a 1 year high of $7.55.

Analysts Set New Price Targets

Several research analysts recently issued reports on AQST shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Aquestive Therapeutics in a research note on Wednesday, October 8th. Zacks Research upgraded shares of Aquestive Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Friday, October 17th. Oppenheimer lifted their target price on shares of Aquestive Therapeutics from $7.00 to $8.00 and gave the stock an “outperform” rating in a report on Monday, September 8th. Citigroup reaffirmed an “outperform” rating on shares of Aquestive Therapeutics in a report on Thursday, October 9th. Finally, JMP Securities lifted their target price on shares of Aquestive Therapeutics from $9.00 to $12.00 and gave the stock a “market outperform” rating in a report on Thursday, October 9th. Two investment analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $10.33.

Insider Activity at Aquestive Therapeutics

In other news, COO Cassie Jung sold 67,575 shares of the firm’s stock in a transaction dated Wednesday, October 15th. The shares were sold at an average price of $7.01, for a total transaction of $473,700.75. Following the sale, the chief operating officer owned 240,771 shares of the company’s stock, valued at $1,687,804.71. This trade represents a 21.92% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Daniel Barber sold 91,343 shares of the firm’s stock in a transaction dated Friday, September 26th. The shares were sold at an average price of $6.03, for a total transaction of $550,798.29. Following the sale, the chief executive officer directly owned 923,430 shares in the company, valued at approximately $5,568,282.90. The trade was a 9.00% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 276,770 shares of company stock worth $1,692,203. 7.85% of the stock is owned by insiders.

Institutional Trading of Aquestive Therapeutics

A number of institutional investors have recently made changes to their positions in AQST. BNP Paribas Financial Markets boosted its holdings in shares of Aquestive Therapeutics by 78.3% in the second quarter. BNP Paribas Financial Markets now owns 9,413 shares of the company’s stock worth $31,000 after buying an additional 4,134 shares during the last quarter. Modern Wealth Management LLC purchased a new position in shares of Aquestive Therapeutics in the second quarter worth approximately $33,000. The Manufacturers Life Insurance Company boosted its holdings in shares of Aquestive Therapeutics by 16.6% in the second quarter. The Manufacturers Life Insurance Company now owns 32,073 shares of the company’s stock worth $106,000 after buying an additional 4,557 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Aquestive Therapeutics by 6.0% in the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 47,098 shares of the company’s stock worth $156,000 after buying an additional 2,649 shares during the last quarter. Finally, Jane Street Group LLC purchased a new position in shares of Aquestive Therapeutics in the second quarter worth approximately $217,000. Hedge funds and other institutional investors own 32.45% of the company’s stock.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.